These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 15933486)

  • 21. Treatment of psoriatic arthritis with etanercept, a tumour necrosis factor antagonist.
    Wong VK; Lebwohl MG
    Expert Opin Biol Ther; 2005 Nov; 5(11):1505-13. PubMed ID: 16255653
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Generalised pustular psoriasis induced by cyclosporin a withdrawal responding to the tumour necrosis factor alpha inhibitor etanercept.
    Kamarashev J; Lor P; Forster A; Heinzerling L; Burg G; Nestle FO
    Dermatology; 2002; 205(2):213-6. PubMed ID: 12218252
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectiveness and safety of etanercept in patients with psoriatic arthritis in a Canadian clinical practice setting: the REPArE trial.
    Gladman DD; Bombardier C; Thorne C; Haraoui B; Khraishi M; Rahman P; Bensen W; Syrotuik J; Poulin-Costello M
    J Rheumatol; 2011 Jul; 38(7):1355-62. PubMed ID: 21572156
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Etanercept (Enbrel) -- an update.
    Goffe B
    Skin Therapy Lett; 2004 Dec-2005 Jan; 9(10):1-4, 9. PubMed ID: 15657632
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Etanercept: a new era in the treatment of psoriatic arthritis.
    Mease PJ
    Am J Manag Care; 2002 Apr; 8(6 Suppl):S181-93. PubMed ID: 11990863
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Successful use of etanercept in acquired angioedema in a patient with psoriatic arthritis.
    Rottem M; Mader R
    J Rheumatol; 2010 Jan; 37(1):209. PubMed ID: 20040647
    [No Abstract]   [Full Text] [Related]  

  • 27. Efficacy and safety of subcutaneous anti-tumor necrosis factor-alpha agents, etanercept and adalimumab, in elderly patients affected by psoriasis and psoriatic arthritis: an observational long-term study.
    Esposito M; Giunta A; Mazzotta A; Zangrilli A; Babino G; Bavetta M; Perricone R; Chimenti S; Chimenti MS
    Dermatology; 2012; 225(4):312-9. PubMed ID: 23295383
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Psoriatic arthritis patients doing better on infliximab than etanercept.
    Smith N; Gadsby K; Deighton C
    Rheumatology (Oxford); 2007 Apr; 46(4):721-2. PubMed ID: 17314216
    [No Abstract]   [Full Text] [Related]  

  • 29. Cytokine blockers in psoriatic arthritis.
    Mease PJ
    Ann Rheum Dis; 2001 Nov; 60 Suppl 3(Suppl 3):iii37-40. PubMed ID: 11890650
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development of lepromatous leprosy following etanercept treatment for arthritis.
    Lydakis C; Ioannidou D; Koumpa I; Giannikaki E; Thalassinos E; Krasoudaki E; Miyakis S
    Clin Rheumatol; 2012 Feb; 31(2):395-8. PubMed ID: 22170033
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumor necrosis factor-alpha inhibition and VATER association: a causal relationship.
    Carter JD; Valeriano J; Vasey FB
    J Rheumatol; 2006 May; 33(5):1014-7. PubMed ID: 16652431
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Henoch Schönlein purpura following etanercept treatment of rheumatoid arthritis.
    Duffy TN; Genta M; Moll S; Martin PY; Gabay C
    Clin Exp Rheumatol; 2006; 24(2 Suppl 41):S106. PubMed ID: 16859610
    [No Abstract]   [Full Text] [Related]  

  • 33. Spotlight on etanercept in rheumatoid arthritis, psoriatic arthritis and juvenile rheumatoid arthritis.
    Culy CR; Keating GM
    BioDrugs; 2003; 17(2):139-45. PubMed ID: 12641492
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Arthralgia as an adverse event to infliximab: a reactive arthritis or triggering of psoriatic arthritis? Successful management by switching to etanercept.
    Moustou AE; Stratigos AJ; Vergou T; Gregoriou S; Georgala S; Danopoulou I
    J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):968-9. PubMed ID: 19207660
    [No Abstract]   [Full Text] [Related]  

  • 35. Etanercept: an updated review of its use in rheumatoid arthritis, psoriatic arthritis and juvenile rheumatoid arthritis.
    Culy CR; Keating GM
    Drugs; 2002; 62(17):2493-537. PubMed ID: 12421111
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of rheumatoid arthritis with etanercept.
    Genovese MC; Kremer JM
    Rheum Dis Clin North Am; 2004 May; 30(2):311-28, vi-vii. PubMed ID: 15172043
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Etanercept for severe psoriasis and psoriatic arthritis: observations on combination therapy.
    Iyer S; Yamauchi P; Lowe NJ
    Br J Dermatol; 2002 Jan; 146(1):118-21. PubMed ID: 11841377
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Angio-oedema in a patient treated with etanercept for rheumatoid arthritis.
    Sendur OF; Turan Y; Berkit IK; Tastaban E
    Basic Clin Pharmacol Toxicol; 2009 Jun; 104(6):488-90. PubMed ID: 19371261
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Etanercept for severe psoriasis and psoriatic arthritis: observations on combination therapy.
    Davison SC; Bunker CB; Basarab T
    Br J Dermatol; 2002 Oct; 147(4):831-2; author reply 832. PubMed ID: 12366452
    [No Abstract]   [Full Text] [Related]  

  • 40. Imported case of visceral leishmaniasis presenting as pancytopenia in a Norwegian patient treated with methotrexate and etanercept for psoriasis arthritis.
    Besada E; Njålla RJ; Nossent JC
    Rheumatol Int; 2013 Oct; 33(10):2687-9. PubMed ID: 22886470
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.